Delving into the Latest Updates on Multivalent HIV-1 peptide immunogen vaccine(National Institute of Allergy & Infectious Diseases) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide vaccine, Prophylactic vaccine

Synonyms-

Target

env

Action

inhibitors

Mechanism

env inhibitors(Recombinant envelope protein inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

HIV Infections

Originator Organization

National Institute of Allergy & Infectious Diseases

Active Organization-

Inactive Organization

National Institute of Allergy & Infectious Diseases

United Biomedical, Inc.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

To evaluate, in healthy adult volunteers, the safety and immunogenicity of multivalent HIV-1 peptide immunogen, a formulation of HIV-1 gp120 principal neutralizing domain (PND) branched synthetic peptides from 15 viral strains representative of diverse worldwide isolates.
Because there is considerable variation among HIV-1 virus strains from differing geographical locations worldwide, a multivalent peptide vaccine has been constructed to include prevalent and divergent isolates, potentially providing for wide coverage of geographically isolated epidemics.

Start Date-

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT00000846

/ CompletedPhase 1IIT

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

To evaluate safety and immunogenicity of 2 different HIV-1 peptide candidate vaccines, the UBI HIV-1 MN PND peptide immunogen and the UBI microparticulate monovalent HIV-1 MN branched peptide when administered sequentially by 2 different routes of immunization, parental priming followed by oral boosting.

Start Date-

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

100 Clinical Results associated with Multivalent HIV-1 peptide immunogen vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

100 Translational Medicine associated with Multivalent HIV-1 peptide immunogen vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

100 Patents (Medical) associated with Multivalent HIV-1 peptide immunogen vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data

100 Deals associated with Multivalent HIV-1 peptide immunogen vaccine(National Institute of Allergy & Infectious Diseases)

Login to view more data